Using this threshold, kinase activity on 10 μM imatinib treatment was decreased in 6 substrates (4.2%) in NCC-DFSP1-C1, 9 substrates (6.3%) in NCC-DFSP3-C1, 7 substrates (4.9%) in NCC-DFSP4-C1, 3 substrates (2.1%) in NCC-DGFP5-C1, and 52 substrates (36.6%) in GIST-T1. This evidence concerns the gene SLC12A3 and gastrointestinal stromal tumor.